Loading...
Endocrinology Billing Services
Much of an endocrinology practice's revenue repeats every month: CGM interpretation (95251), remote physiologic monitoring (99453–99458), and chronic or principal care management. Each code has its own time, device-day, and consent rules. Qualigenix bills these monthly services alongside your visits and codes diabetes, thyroid, and pituitary diagnoses to the specificity that risk adjustment requires.
How Endocrinology Billing Works
Endocrinology billing combines visit coding with monthly services (CGM interpretation, remote physiologic monitoring, and care management), prior authorization for CGMs, pumps, growth hormone, and osteoporosis drugs, and diagnosis coding specific enough for risk adjustment. Qualigenix's coders bill endocrinology practices and diabetes centers with a 98.2% first-pass clean claim rate on first submission. Start with a free billing audit at 786-259-0231.
01
Diagnosis Specificity and HCCs
A diabetes code without its documented complications (E11.9 instead of a code for diabetic kidney disease or neuropathy) understates the patient's risk under the CMS-HCC model and affects Medicare Advantage and value-based payments. The same applies to pituitary and adrenal disorders.
01
Device and Drug Prior Auth
CGMs and insulin pumps need prior authorization or coverage documentation from most payers, and growth hormone and osteoporosis drugs such as denosumab and romosozumab are approved case by case. A lapsed approval stops payment while the patient keeps using the device or drug.
01
Monthly Time Thresholds
CGM start-up (95249, 95250) needs at least 72 hours of data, and CPT allows 95251 interpretation no more than once a month. Remote physiologic monitoring device supply (99454) needs 16 or more days of readings in 30 days, and management (99457, 99458) needs 20-minute increments of interactive time. Starting in 2026, CMS added codes for 2–15 days of readings (99445) and for the first 10 minutes of management (99470).
01
Telehealth Diabetes Follow-Ups
Diabetes follow-ups by video are common in endocrinology, and payers set different rules for place of service, modifier 95, and audio-only visits. A rule that paid last year can deny this year.
01
Medicare CGM Criteria
Medicare covers CGMs under the glucose monitor LCD (L33822) for patients treated with insulin or with a documented history of problematic hypoglycemia. CGM devices and supplies are billed through DME channels, so the practice's documentation has to support the supplier's claim.
01
Data Review Documentation
CGM interpretation needs a documented review and report, RPM needs patient consent and device-day counts, and care management needs consent and monthly time logs. Without them, each monthly claim is open to denial and recoupment.
01
Recurring Denials
The recurring endocrinology denials come from stimulation and suppression tests (80400–80439) billed without the infusion or injection codes, DXA billed sooner than Medicare's 24-month frequency limit without documented medical necessity, and in-office zoledronic acid or denosumab billed without authorization or with the wrong units.
01
Program Compliance
Remote monitoring, care management, and diabetes self-management training each carry program rules: RPM device-day and consent requirements, CCM consent and time minimums, and DSMT accreditation by a recognized national program.
How Qualigenix Captures Every Endocrine Service You Deliver
Qualigenix captures endocrine services by billing monthly monitoring and care management on a fixed cycle and reviewing diagnosis specificity on every claim.
Specificity-First Coding
Coders read each note for documented complications and code diabetes, thyroid, and pituitary conditions to the most specific code the documentation supports.
Device and Drug Auth Tracking
We track every CGM, pump, growth hormone, and osteoporosis drug approval by expiration date and request renewals before they lapse.
Monthly Billing Cycles
At month end, we reconcile device days and logged minutes for each enrolled patient and bill the codes each patient qualifies for.
Payer-Specific Telehealth Billing
We keep a payer-by-payer telehealth rule set for place of service, modifiers, and audio-only coverage, and update it when payers change policy.
Pre-Order Device Checks
We check payer device criteria, including Medicare's glucose monitor LCD, before the device is ordered, and send the supplier the documentation it needs.
Monitoring Documentation Checks
We flag CGM reports without an interpretation, RPM months under the device-day threshold, and care-management months without consent before billing.
Denial Appeals
Our denial team overturns 79% of the denials it works, with an average appeal turnaround under 9 days. Appeals include the medical-necessity documentation and payer policy for each test or drug.
Program Compliance Monitoring
We audit RPM, CCM, and DSMT claims each month for consent, device days, time, and program accreditation.
CASE STUDY 01
How a 3-provider podiatry group cleared $214K in aged A/R
THE SITUATION
A 3-provider podiatry group with roughly 60% Medicare payer mix carried $412,000 in A/R, 38% of it past 120 days. Routine foot care claims (11720, 11721, 11055–11057) had stalled on inconsistent Q7/Q8/Q9 modifiers and class-finding documentation, so payers held or partially paid and nobody worked the remainder. Medicare crossover to secondaries was not being posted, and small patient balances were written off.
WHAT QUALIGENIX DID
We ran a full A/R aging segmentation, worked claims by payer and denial reason rather than by date, rebilled the stalled routine-care claims with corrected modifiers, and reactivated secondary and crossover billing.
Key Outcomes & Turnaround
38% to 14%A/R past 120 days
$214,000recovered from aged A/R
90 daysto turn it around
~60%Medicare payer mix
Audited Practice Results
How a solo podiatrist lifted first-pass acceptance to 96%
THE SITUATION
A solo podiatrist coding 320 encounters a month was stuck at 82% first-pass acceptance. Routine foot care went out without the systemic-condition diagnosis pairing and class findings Medicare requires, so it read as non-covered. Wound debridement was coded to the wrong depth (11042 for skin and subcutaneous where the note supported 11043 for muscle and fascia). Same-day E/M with a procedure went out without modifier 25 and got bundled.
WHAT QUALIGENIX DID
We rebuilt the coding workflow: diagnosis-to-CPT pairing rules for at-risk foot care, correct Q-modifier logic, depth-based debridement coding tied to the operative note, and disciplined use of modifiers 25 and 59/XS.
Key Outcomes & Turnaround
82% to 96%first-pass acceptance
+11%per-encounter reimbursement
60 daysto turn it around
320/moencounters coded
Audited Practice Results
How a 2-location podiatry practice cut its denial rate by two-thirds
THE SITUATION
A 2-location podiatry practice sat at a 19% denial rate, mostly Medicare routine-foot-care and nail-debridement rejections. The denials clustered in three buckets: medical-necessity rejections on routine foot care (missing qualifying diagnosis and class findings), frequency-edit denials on nail debridement billed inside the 60-day window, and missing Q modifiers that flagged services as non-covered.
WHAT QUALIGENIX DID
We built a front-end denial-prevention layer, checking eligibility and coverage against payer LCDs before claims went out, plus a structured appeal workflow with documentation templates mapped to each denial reason.
Key Outcomes & Turnaround
19% to 6%denial rate
$68,000recovered on appealed claims
4 monthsto turn it around
2 locationspractice size
Audited Practice Results
Endocrinology Coding Across Diabetes, Thyroid, Bone, and Hormone Care
Qualigenix codes endocrinology by service line, because diabetes technology, thyroid procedures, bone density, and hormone testing each follow different rules.
Diabetes Visits and Education
Codes: 99202–99215, G0108, G0109, 97802–97804. Office visits, individual and group diabetes self-management training through an accredited program, and medical nutrition therapy by a registered dietitian.
COMPLIANCE
Endocrine Practices We Support
Qualigenix supports endocrinology practices, diabetes care centers, metabolic and obesity clinics, thyroid specialty centers, osteoporosis programs, pediatric endocrinology, hospital-based endocrinology departments, and multi-specialty medical groups.
0%
Audit Pass Rate
<0%
Variance Threshold
Why Qualigenix
0%
IMPROPER PAYMENT RATE
0%
FROM DOC GAPS
0%
FROM CODING ERRORS
$0M+
PAID IN ERROR
QUESTIONS BUYERS ASK
Qualigenix prices endocrinology billing after reviewing your visit volume, monitoring programs, payer mix, and the services you want to hand over. Most practices start with a free billing audit so the quote reflects real numbers.
Yes, when each month meets the code's requirements. CPT allows CGM interpretation (95251) no more than once a month, and RPM device supply (99454) needs 16 or more days of readings in 30 days, with the new 2026 code 99445 covering 2–15 days.
We bill RPM and CCM only when patient consent, device days, and time are documented for that month, and we audit enrolled patients every month. A free audit shows which of your monthly claims carry documentation gaps.
Yes. We work aging endocrinology claims by denial reason and timely-filing limit, starting with the highest-value accounts. A free AR review shows how much is still recoverable.
We submit device and drug authorizations with the clinical criteria each payer requires, track every approval by expiration date, and request renewals before they lapse.
Yes. We bill video and audio-only diabetes visits under each payer's current telehealth rules for place of service, modifiers, and covered services.
Qualigenix works across 133 EMR/EHR platforms. We confirm access to your EHR and glucose data platforms during the free billing audit.
Qualigenix's average onboarding time is 6 days. That covers system access, payer enrollment checks, and coder assignment before we take over claim submission.